FDA advisory panel votes 10-3 in favor of Replimune's melanoma drug

July 30, 2026 6:15 PM

Replimune Group, Inc. (Nasdaq: REPL) announced that the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found